Dr. Richard Friedman, a professor of clinical psychiatry at Weill Cornell Medical School, told The Daily Beast that the company’s claims “cannot be taken seriously by scientists, clinicians, and, most importantly, the public,” until they are peer-reviewed.
“The history of predictive biomarkers is a bit like the search for the Holy Grail,” he told the news site. “They promise a lot, but in the end provide little advantage over what clinicians do in everyday practice: take a careful history of the symptoms and treatment response.”